While it is nice to see several analysts looking at, and apparently liking Insmed, for the most part their price targets and sales projections are based on European sales of arikace for CF, and US sales of arikace for NTM. At least one did mention at least the potential of arikace treating other pulmonary infections.
The worldwide market for CF and NTM infection may be over a billion dollars, but the worldwide market for all pulmonary infections is many times that.
Everyone interested in Insmed should look at their current slide show. Part of it focuses on what the company now calls: Orphan 2.0. This appears in a hexagon on the top right. Their are two more hexagons. One has just one word: Pulmonary. The other has: Infectious Disease.
Insmed is letting the analysts know that while current trials are focused on orphan disease, with decent market potential, the vision of the company and their lead product addresses a significantly larger, broader market. The Insmed story is getting exciting.
Being granted QIDP status will cause another round of analyst price hikes, as the company's vision will begin to move forward with a strong stamp of approval from the FDA.
JMHO, strong phase III results, along with the granting of QIDP could propel these shares to levels most here likely don't anticipate. If we add in just one or two more iPLEX licensing agreements.....this potentially could become one of the really nice biotech stories of the next several years.
Scalp, there are many here that would love to answer that question. In a nutshell, it could become one of the most significant drugs in world history, or it may stay nearly shelved as it has for the past several years. Insmed owns the rights.